VISMODEGIB for Basal cell naevus syndrome: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 129 adverse event reports in the FDA FAERS database where VISMODEGIB was used for Basal cell naevus syndrome.
Most Reported Side Effects for VISMODEGIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Muscle spasms | 1,937 | 23.8% | 24 | 110 |
| Alopecia | 1,330 | 16.4% | 28 | 81 |
| Ageusia | 958 | 11.8% | 7 | 49 |
| Fatigue | 899 | 11.1% | 20 | 78 |
| Dysgeusia | 706 | 8.7% | 18 | 40 |
| Weight decreased | 688 | 8.5% | 19 | 59 |
| Nausea | 669 | 8.2% | 8 | 72 |
| Decreased appetite | 662 | 8.1% | 21 | 69 |
| Death | 657 | 8.1% | 641 | 23 |
| Diarrhoea | 446 | 5.5% | 16 | 48 |
| Constipation | 361 | 4.4% | 3 | 31 |
| Off label use | 335 | 4.1% | 24 | 24 |
| Asthenia | 274 | 3.4% | 14 | 52 |
| Arthralgia | 264 | 3.3% | 0 | 20 |
| No adverse event | 247 | 3.0% | 1 | 0 |
Other Indications for VISMODEGIB
Basal cell carcinoma (5,329)
Product used for unknown indication (1,417)
Skin cancer (452)
Neoplasm malignant (124)
Congenital anomaly (54)
Medulloblastoma (52)
Squamous cell carcinoma of skin (42)
Malignant melanoma (38)
Neoplasm (36)
Neoplasm skin (36)